Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
Katharina HablerAnne-Sophie KallaMichael RychlikMathias BruegelDaniel TeupserSusanne NährigMichael VogeserMichael PaalPublished in: Clinical chemistry and laboratory medicine (2021)
We hereby present a robust and highly selective isotope dilution liquid chromatography tandem mass spectrometry (ID-LC-MS/MS) assay for the simultaneous quantification of the so far approved CFTR modulators and their metabolites in human serum. The assay is suitable for state-of-the-art pharmacovigilance of CFTR modulator therapy in CF patients, in order to maximize safety and efficacy, and also to establish dose-response relationships in clinical trials.
Keyphrases
- cystic fibrosis
- liquid chromatography tandem mass spectrometry
- ms ms
- pseudomonas aeruginosa
- simultaneous determination
- lung function
- clinical trial
- end stage renal disease
- gas chromatography
- small molecule
- solid phase extraction
- high throughput
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- transcription factor
- mass spectrometry
- emergency department
- randomized controlled trial
- bone marrow
- drug induced
- drug administration
- adverse drug
- electronic health record